Aprio Wealth Management LLC Purchases 12,871 Shares of Medtronic PLC $MDT

Key Points

• Aprio Wealth Management boosted its stake in Medtronic by 341.6% in Q4, buying 12,871 shares to hold 16,639 shares worth about $1.598 million.
• Insider sale: EVP Harry "Skip" Kiil sold 52,524 shares at roughly $97.71 (~$5.13M), cutting his ownership by 61.58%; corporate insiders own just 0.26% of the company.
• Medtronic slightly beat quarterly EPS estimates ($1.36 vs. $1.34) with revenue up 5.8%, set FY26 EPS guidance of 5.62–5.66, pays a $0.71 quarterly dividend (3.4% yield), and carries a consensus analyst target of $107.80 ("Moderate Buy").

Aprio Wealth Management LLC boosted its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 341.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,639 shares of the medical technology company's stock after acquiring an additional 12,871 shares during the quarter. Aprio Wealth Management LLC's holdings in Medtronic were worth $1,598,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MDT. Corundum Trust Company INC bought a new stake in shares of Medtronic during the 3rd quarter valued at about $27,000. Lodestone Wealth Management LLC bought a new position in shares of Medtronic in the 4th quarter worth approximately $27,000. Valley Wealth Managers Inc. bought a new position in shares of Medtronic in the 3rd quarter worth approximately $29,000. Board of the Pension Protection Fund purchased a new position in shares of Medtronic in the fourth quarter worth approximately $29,000. Finally, GoalVest Advisory LLC purchased a new position in shares of Medtronic in the fourth quarter worth approximately $29,000. Institutional investors own 82.06% of the company's stock.

Insider Buying and Selling

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Price Performance

Shares of NYSE:MDT opened at $83.36 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 1-year low of $79.93 and a 1-year high of $106.33. The company has a market capitalization of $107.03 billion, a P/E ratio of 23.22, a P/E/G ratio of 2.16 and a beta of 0.75. The firm's 50 day simple moving average is $89.78 and its two-hundred day simple moving average is $95.22.

Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period in the prior year, the business posted $1.38 earnings per share. The company's revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.4%. Medtronic's dividend payout ratio (DPR) is currently 79.11%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Argus reduced their target price on shares of Medtronic from $125.00 to $115.00 and set a "buy" rating for the company in a report on Monday, April 6th. Citigroup dropped their price target on shares of Medtronic from $117.00 to $110.00 and set a "buy" rating on the stock in a research note on Tuesday, April 7th. Wells Fargo & Company started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an "overweight" rating and a $114.00 price objective for the company. Daiwa Securities Group reduced their price objective on Medtronic from $117.00 to $115.00 and set a "buy" rating for the company in a research note on Friday, February 27th. Finally, Wall Street Zen cut Medtronic from a "buy" rating to a "hold" rating in a report on Saturday, April 11th. Fifteen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Medtronic currently has an average rating of "Moderate Buy" and a consensus target price of $107.80.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Completed CathWorks acquisition and $100M investment in Pulnovo expand Medtronic’s AI and cardiovascular diagnostics/therapy footprint — these moves boost long‑term addressable market and product pipeline relevance. Medtronic Expands AI Heart Care As Investors Weigh Valuation And Momentum
• Positive Sentiment: Market reports highlight sizable growth opportunities (automated insulin delivery, catheters, long‑term/home healthcare) where Medtronic is a listed participant — supports longer‑term revenue runway assumptions. 2026 HoustonCISO ORBIE Awards Recognize Top Security Executives
• Neutral Sentiment: Analysts (Jefferies) reiterate a Hold with a $95 target, reflecting valuation compression and a slower growth outlook; not a catalyst for a large rerating but keeps expectations muted. Medtronic: Portfolio Streamlining and Diabetes Spin-Off Benefits Offset by Lower Growth Outlook and Valuation Compression, Justifying Hold Rating
• Neutral Sentiment: Investor interest pieces and valuation checks note new GE HealthCare tie‑ups and the Altaviva launch — positive strategic context but likely already priced in and awaiting earnings results for confirmation. Medtronic (MDT) Valuation Check As New GE HealthCare Tie Up And Altaviva Launch Draw Investor Interest
• Negative Sentiment: Pre‑earnings coverage flags an expected single‑digit drop in quarterly profits — raises the risk of a downside surprise and is a chief near‑term pressure on the stock. What You Need to Know Ahead of Medtronic's Earnings Release
• Negative Sentiment: UBS issued a pessimistic forecast for MDT’s stock price — an explicit bearish view that can amplify selling pressure, particularly with earnings imminent. UBS Group Issues Pessimistic Forecast for Medtronic NYSE: MDT Stock Price
• Negative Sentiment: Several investor commentaries (including Seeking Alpha) maintain a Hold view citing slow growth, high debt and competitive pressures (HUGO robotics, diabetes spin‑off uncertainties), signaling limited near‑term upside without clearer execution. Medtronic: Is This Dividend Aristocrat Finally A "Buy" Before Earnings?

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.